Cargando…
Is CDK9 a promising target for both primary and metastatic osteosarcoma?
Autor principal: | Qin, Jiang-Jiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413331/ https://www.ncbi.nlm.nih.gov/pubmed/30651218 http://dx.doi.org/10.1016/j.ebiom.2019.01.016 |
Ejemplares similares
-
Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma
por: Heijkants, Renier, et al.
Publicado: (2017) -
Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma
por: Ma, Hangzhan, et al.
Publicado: (2018) -
Cdk2 and Cdk4 cooperatively control the expression of Cdc2
por: Berthet, Cyril, et al.
Publicado: (2006) -
CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles
por: Dai, Wei-Jing, et al.
Publicado: (2016) -
CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies
por: Morillo, Daniel, et al.
Publicado: (2023)